Skip to main content
Clinical Trials/NCT05493735
NCT05493735
Completed
Phase 3

Lidocaine for Pessary Removal and Reinsertion Pain Reduction

University of South Florida1 site in 1 country66 target enrollmentSeptember 8, 2022

Overview

Phase
Phase 3
Intervention
Placebo Jelly
Conditions
Pelvic Organ Prolapse
Sponsor
University of South Florida
Enrollment
66
Locations
1
Primary Endpoint
Change in patient's pain using the visual analog scale (VAS) after pessary removal
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The primary objective of this study is to estimate the effect of lidocaine jelly on patient pain at the time of office pessary removal.

Detailed Description

The purpose of the study is to investigate the effects of lidocaine jelly on patient pain at the time of office pessary removal and reinsertion. All patients presenting to the University of South Florida Urogynecology clinic for a pessary maintenance appointment or "pessary check" will be screened as potential study participants. After being informed of risks and benefits of participation, informed consent will be obtained. Patients will be randomized into two groups: the control group or experimental group. The patient will complete a brief questionnaire and pain assessment using a Visual Analog Scale (VAS). Patients will be blinded. The investigators will be unblinded. The investigators will apply the jelly (lidocaine vs lubricating). The participant will have an equal chance of being in the control arm or experimental arm. After 5 minutes, the investigator will assess the patient's genital hiatus with valsalva and proceed with pessary removal per the investigator's routine. The patient will complete another VAS to indicate pain level after pessary removal. The investigator will perform a speculum exam per routine and then reinsert the pessary. The patient will complete a final VAS to indicate level of pain after pessary reinsertion along with a brief final questionnaire.

Registry
clinicaltrials.gov
Start Date
September 8, 2022
End Date
June 30, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Women aged 18 years or older
  • Presenting for routine pessary management for prolapse, stress urinary incontinence, or both with a pessary in place
  • able to provide written informed consent
  • able to complete the visual analog scale

Exclusion Criteria

  • Women less than 18 years of age.
  • Patients who speak neither English nor Spanish
  • Pregnancy
  • Medical contraindication to lidocaine
  • Planned change in pessary size or type
  • Patients who remove and reinsert their pessary at home

Arms & Interventions

Control

Lubricating jelly (placebo) will be placed in the vagina to the level of the pessary, five minutes prior to pessary removal.

Intervention: Placebo Jelly

Experimental

Lidocaine jelly will be placed in the vagina to the level of the pessary, five minutes prior to the pessary removal.

Intervention: Lidocaine Hcl 2% Jelly

Outcomes

Primary Outcomes

Change in patient's pain using the visual analog scale (VAS) after pessary removal

Time Frame: 0 and 5 minutes

Self-reported pain level at time of pessary removal controlling for baseline pain. Scale is from 0 to 10 (0=no pain and 10=worst pain)

Secondary Outcomes

  • Change in patient's pain using the visual analog scale (VAS) after pessary reinsertion(0 and 10 minutes)
  • Genital Hiatus with Valsalva(0 minutes)

Study Sites (1)

Loading locations...

Similar Trials